HUTCHMED (LON:HCM) Sets New 1-Year Low – Should You Sell?

HUTCHMED (China) Limited (LON:HCM)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 191.98 and last traded at GBX 193, with a volume of 35840 shares. The stock had previously closed at GBX 198.

HUTCHMED Stock Performance

The company has a market capitalization of £1.66 billion, a price-to-earnings ratio of 3.64 and a beta of 0.45. The company has a current ratio of 4.96, a quick ratio of 2.97 and a debt-to-equity ratio of 7.91. The stock’s fifty day simple moving average is GBX 211.60 and its 200-day simple moving average is GBX 215.37.

About HUTCHMED

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).